Category: Misc

    • Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
    • Berkel C, Cacan E.
    • Biochem Biophys Res Commun. 2021 Jul 14;570:74-81. doi: 10.1016/j.bbrc.2021.07.004. Epub ahead of print.

    • Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation.
    • Majumder MA, Blank ML, Geary J, Bollinger JM, Guerrini CJ, Robinson JO, Canfield I, Cook-Deegan R, McGuire AL.
    • J Pers Med. 2021 Jul 8;11(7):646. doi: 10.3390/jpm11070646.

    • Suppression of DNA Polymerase ß Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
    • Yuhas SC, Mishra A, DeWeese TL, Greenberg MM.
    • ACS Chem Biol. 2021 Jul 9. doi: 10.1021/acschembio.1c00385. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • One Woman’s Breast Cancer Journey: It’s Not Just About the Breast.
    • [No author given]
    • FORCE. Blog. 2021 Jun 21.

    Related:

    Information: It's Not (Just) About the Breast. (Well Strong Courage)

    • The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks.
    • van Wijk LM, Kramer CJH, Vermeulen S, ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG.
    • Cancers (Basel). 2021 Jun 18;13(12):2994. doi: 10.3390/cancers13122994.

    • Breast specific molecular clocks comprised of ELF5 expression and promoter methylation identify individuals susceptible to cancer initiation.
    • Miyano M, Sayaman RW, Shalabi SF, Senapati P, Lopez JC, Angarola BL, Hinz S, Zirbes A, Anczukow O, Yee LD, Sedrak MS, Stampfer MR, Seewaldt VL, LaBarge MA.
    • Cancer Prev Res (Phila). 2021 Jun 17:canprevres.CAPR-20-0635-A.2020. doi: 10.1158/1940-6207.CAPR-20-0635. Epub ahead of print.

    • A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors.
    • Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Färkkilä A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D’Andrea AD.
    • Nat Cancer. 2021 Jun 17:1-2. doi: 10.1038/s43018-021-00203-x. Epub ahead of print.

    Related:

    Press: Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors (Clinical OMICs)

    • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    • Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ.
    • Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8.

    • PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
    • Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q.
    • NPJ Precis Oncol. 2021 Jun 9;5(1):49. doi: 10.1038/s41698-021-00189-w.

    • Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    • Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS.
    • Eur Urol. 2021 Jun 5:S0302-2838(21)01799-1. doi: 10.1016/j.eururo.2021.05.030. Epub ahead of print.

    • BRCA1-BRCT Mutations Alter the Subcellular Localization of BRCA1 In Vitro.
    • Drikos I, Boutou E, Kastritis PL, Vorgias CE.
    • Anticancer Res. 2021 Jun;41(6):2953-2962. doi: 10.21873/anticanres.15077.

    • Generation and characterization of induced pluripotent stem cells heterozygous for the Portuguese BRCA2 founder mutation.
    • Silva TP, Pereira CA, Raposo AC, Oliveira AR, Arez M, Cabral JMS, Milagre I, Carmo-Fonseca M, Rocha STD.
    • Stem Cell Res. 2021 May;53:102364. doi: 10.1016/j.scr.2021.102364. Epub 2021 Apr 23.

    • LitAlert ~~ GeneLit.com

    • High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
    • Satyananda V, Oshi M, Endo I, Takabe K.
    • Ann Surg Oncol. 2021 May 8. doi: 10.1245/s10434-021-10063-5. Epub ahead of print.

    Related:

    Commentary:

    ASO Author Reflections: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.

    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Marjolijn Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.